Skip to main content
Erschienen in: Journal of Assisted Reproduction and Genetics 7/2016

24.03.2016 | Reproductive Physiology and Disease

Follicular fluid soluble receptor for advanced glycation endproducts (sRAGE): a potential protective role in polycystic ovary syndrome

verfasst von: BiJun Wang, MengMeng Hao, QingLing Yang, Jing Li, YiHong Guo

Erschienen in: Journal of Assisted Reproduction and Genetics | Ausgabe 7/2016

Einloggen, um Zugang zu erhalten

Abstract

Purpose

To explore the relationships between the soluble receptor for advanced glycation endproducts (sRAGE) and the outcome parameters following in vitro fertilization-embryo transfer (IVF-ET) in patients with polycystic ovary syndrome (PCOS) and investigate the protective effect of sRAGE in PCOS development regarding inflammation.

Methods

We conducted a prospective analysis of a subsample of 74 participants from the Reproductive Medical Center of the First Affiliated Hospital of Zhengzhou University. We quantified sRAGE, vascular endothelial growth factor (VEGF), tumor necrosis factor (TNF-α), interleukelin-6 (IL-6), and C-reactive protein (CPR) protein levels in the follicular fluid from 39 PCOS and 35 non-PCOS reproductive-age women. sRAGE and VEGF, TNF-α, IL-6, and CRP in follicular fluid aspirated without blood were measured by ELISA.

Results

sRAGE concentrations in the follicular fluid were significantly lower in the PCOS group compared to those in the control group, while VEGF, TNF-α, IL-6, and CRP concentrations were significantly higher in the PCOS group than in the control group (P < 0.05). sRAGE was significantly, inversely correlated with the total dose of gonadotropin (Gn) in the PCOS group undergoing IVF treatment (r = −0.451, P = 0.004). After adjusting for age and Gn dose (in international units used per cycle), sRAGE protein levels in the follicular fluid were significantly, inversely related to VEGF (r = −0.378, P = 0.018), TNF-α (r = −0.450, P = 0.004), IL-6 (r = −0.455, P = 0.004), and CRP (r = −0.375, P = 0.019).

Conclusion

sRAGE in the follicular fluid might exert a protective effect against the inflammatory action of PCOS development.
Literatur
2.
Zurück zum Zitat Liu M, Gao J, Zhang Y, Li P, Wang H, Ren X, et al. Serum levels of TSP-1, NF-kappaB and TGF-beta1 in polycystic ovarian syndrome (PCOS) patients in northern China suggest PCOS is associated with chronic inflammation. Clin Endocrinol. 2015;83(6):913–22. doi:10.1111/cen.12951.CrossRef Liu M, Gao J, Zhang Y, Li P, Wang H, Ren X, et al. Serum levels of TSP-1, NF-kappaB and TGF-beta1 in polycystic ovarian syndrome (PCOS) patients in northern China suggest PCOS is associated with chronic inflammation. Clin Endocrinol. 2015;83(6):913–22. doi:10.​1111/​cen.​12951.CrossRef
4.
5.
Zurück zum Zitat Palimeri S, Palioura E, Diamanti-Kandarakis E. Current perspectives on the health risks associated with the consumption of advanced glycation end products: recommendations for dietary management. Diabetes, Metab Syndr Obes: Targets Ther. 2015;8:415–26. doi:10.2147/dmso.s63089. Palimeri S, Palioura E, Diamanti-Kandarakis E. Current perspectives on the health risks associated with the consumption of advanced glycation end products: recommendations for dietary management. Diabetes, Metab Syndr Obes: Targets Ther. 2015;8:415–26. doi:10.​2147/​dmso.​s63089.
6.
Zurück zum Zitat Wang YS, Li YY, Wang LH, Kang Y, Zhang J, Liu ZQ, et al. Tanshinone IIA attenuates chronic pancreatitis-induced pain in rats via downregulation of HMGB1 and TRL4 expression in the spinal cord. Pain Physician. 2015;18(4):E615–28.PubMed Wang YS, Li YY, Wang LH, Kang Y, Zhang J, Liu ZQ, et al. Tanshinone IIA attenuates chronic pancreatitis-induced pain in rats via downregulation of HMGB1 and TRL4 expression in the spinal cord. Pain Physician. 2015;18(4):E615–28.PubMed
7.
Zurück zum Zitat Lazo M, Halushka MK, Shen L, Maruthur N, Rebholz CM, Rawlings AM, et al. Soluble receptor for advanced glycation end products and the risk for incident heart failure: the atherosclerosis risk in communities study. Am Heart J. 2015;170(5):961–7. doi:10.1016/j.ahj.2015.08.008.CrossRefPubMed Lazo M, Halushka MK, Shen L, Maruthur N, Rebholz CM, Rawlings AM, et al. Soluble receptor for advanced glycation end products and the risk for incident heart failure: the atherosclerosis risk in communities study. Am Heart J. 2015;170(5):961–7. doi:10.​1016/​j.​ahj.​2015.​08.​008.CrossRefPubMed
8.
Zurück zum Zitat Merhi Z. Advanced glycation end products and their relevance in female reproduction. Human reproduction (Oxford, England). 2014; 29(1): 135–45. doi:10.1093/humrep/det383. Merhi Z. Advanced glycation end products and their relevance in female reproduction. Human reproduction (Oxford, England). 2014; 29(1): 135–45. doi:10.​1093/​humrep/​det383.
9.
Zurück zum Zitat Romero R, Espinoza J, Hassan S, Gotsch F, Kusanovic JP, Avila C, et al. Soluble receptor for advanced glycation end products (sRAGE) and endogenous secretory RAGE (esRAGE) in amniotic fluid: modulation by infection and inflammation. J Perinat Med. 2008;36(5):388–98. doi:10.1515/jpm.2008.076.CrossRefPubMed Romero R, Espinoza J, Hassan S, Gotsch F, Kusanovic JP, Avila C, et al. Soluble receptor for advanced glycation end products (sRAGE) and endogenous secretory RAGE (esRAGE) in amniotic fluid: modulation by infection and inflammation. J Perinat Med. 2008;36(5):388–98. doi:10.​1515/​jpm.​2008.​076.CrossRefPubMed
10.
Zurück zum Zitat Rzepka R, Dolegowska B, Rajewska A, Kwiatkowski S, Salata D, Budkowska M, et al. Soluble and endogenous secretory receptors for advanced glycation end products in threatened preterm labor and preterm premature rupture of fetal membranes. BioMed Res Int. 2015;2015:568042. doi:10.1155/2015/568042.CrossRefPubMedPubMedCentral Rzepka R, Dolegowska B, Rajewska A, Kwiatkowski S, Salata D, Budkowska M, et al. Soluble and endogenous secretory receptors for advanced glycation end products in threatened preterm labor and preterm premature rupture of fetal membranes. BioMed Res Int. 2015;2015:568042. doi:10.​1155/​2015/​568042.CrossRefPubMedPubMedCentral
11.
Zurück zum Zitat Merhi Z, Irani M, Doswell AD, Ambroggio J. Follicular fluid soluble receptor for advanced glycation end-products (sRAGE): a potential indicator of ovarian reserve. J Clin Endocrinol Metab. 2014;99(2):E226–33. doi:10.1210/jc.2013-3839.CrossRefPubMed Merhi Z, Irani M, Doswell AD, Ambroggio J. Follicular fluid soluble receptor for advanced glycation end-products (sRAGE): a potential indicator of ovarian reserve. J Clin Endocrinol Metab. 2014;99(2):E226–33. doi:10.​1210/​jc.​2013-3839.CrossRefPubMed
12.
Zurück zum Zitat Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Human reproduction (Oxford, England). 2004; 19(1): 41–7. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Human reproduction (Oxford, England). 2004; 19(1): 41–7.
13.
Zurück zum Zitat Wu TL, Tsai CC, Wang YY, Ho KY, Wu YM, Hung HC, et al. The association between the RAGE G82S polymorphism, sRAGE and chronic periodontitis in Taiwanese individuals with and without diabetes. J Periodontal Res. 2015;50(6):881–9. doi:10.1111/jre.12282.CrossRefPubMed Wu TL, Tsai CC, Wang YY, Ho KY, Wu YM, Hung HC, et al. The association between the RAGE G82S polymorphism, sRAGE and chronic periodontitis in Taiwanese individuals with and without diabetes. J Periodontal Res. 2015;50(6):881–9. doi:10.​1111/​jre.​12282.CrossRefPubMed
15.
Zurück zum Zitat Yamagishi S, Matsui T. Soluble form of a receptor for advanced glycation end products (sRAGE) as a biomarker. Front biosci (Elite edition). 2010;2:1184–95.CrossRef Yamagishi S, Matsui T. Soluble form of a receptor for advanced glycation end products (sRAGE) as a biomarker. Front biosci (Elite edition). 2010;2:1184–95.CrossRef
16.
Zurück zum Zitat Lee EJ, Park EY, Mun H, Chang E, Ko JY, do Kim Y, et al. Soluble receptor for advanced glycation end products inhibits disease progression in autosomal dominant polycystic kidney disease by down-regulating cell proliferation. FASEB J: Off Publ Fed Am Soc Exp Biol. 2015;29(8):3506–14. doi:10.1096/fj.15-272302.CrossRef Lee EJ, Park EY, Mun H, Chang E, Ko JY, do Kim Y, et al. Soluble receptor for advanced glycation end products inhibits disease progression in autosomal dominant polycystic kidney disease by down-regulating cell proliferation. FASEB J: Off Publ Fed Am Soc Exp Biol. 2015;29(8):3506–14. doi:10.​1096/​fj.​15-272302.CrossRef
17.
18.
19.
21.
Zurück zum Zitat Bonetti TC, Borges Jr E, Braga DP, Iaconelli Jr A, Kleine JP, Silva ID. Intrafollicular soluble receptor for advanced glycation end products (sRAGE) and embryo quality in assisted reproduction. Reprod Biomed Online. 2013;26(1):62–7. doi:10.1016/j.rbmo.2012.10.001.CrossRefPubMed Bonetti TC, Borges Jr E, Braga DP, Iaconelli Jr A, Kleine JP, Silva ID. Intrafollicular soluble receptor for advanced glycation end products (sRAGE) and embryo quality in assisted reproduction. Reprod Biomed Online. 2013;26(1):62–7. doi:10.​1016/​j.​rbmo.​2012.​10.​001.CrossRefPubMed
22.
Zurück zum Zitat Guclu M, Ali A, Eroglu DU, Buyukuysal SO, Cander S, Ocak N. Serum levels of sRAGE are associated with body measurements, but not glycemic parameters in patients with prediabetes. Metab Syndr Relat Disord. 2016;14(1):33–9. doi:10.1089/met.2015.0078.CrossRefPubMed Guclu M, Ali A, Eroglu DU, Buyukuysal SO, Cander S, Ocak N. Serum levels of sRAGE are associated with body measurements, but not glycemic parameters in patients with prediabetes. Metab Syndr Relat Disord. 2016;14(1):33–9. doi:10.​1089/​met.​2015.​0078.CrossRefPubMed
23.
Zurück zum Zitat Uribarri J, del Castillo MD, de la Maza MP, Filip R, Gugliucci A, Luevano-Contreras C et al. Dietary advanced glycation end products and their role in health and disease. 2015. Uribarri J, del Castillo MD, de la Maza MP, Filip R, Gugliucci A, Luevano-Contreras C et al. Dietary advanced glycation end products and their role in health and disease. 2015.
25.
Zurück zum Zitat Stewart C, Cha S, Caudle RM, Berg K, Katz J. Decreased levels of soluble receptor for advanced glycation end products in patients with primary Sjogren’s syndrome. Rheumatol Int. 2008;28(8):771–6. doi:10.1007/s00296-008-0529-4.CrossRefPubMed Stewart C, Cha S, Caudle RM, Berg K, Katz J. Decreased levels of soluble receptor for advanced glycation end products in patients with primary Sjogren’s syndrome. Rheumatol Int. 2008;28(8):771–6. doi:10.​1007/​s00296-008-0529-4.CrossRefPubMed
28.
Zurück zum Zitat Tal R, Seifer DB, Grazi RV, Malter HE. Follicular fluid placental growth factor is increased in polycystic ovarian syndrome: correlation with ovarian stimulation. Reprod Biol Endocrinol: RB&E. 2014;12:82. doi:10.1186/1477-7827-12-82.CrossRef Tal R, Seifer DB, Grazi RV, Malter HE. Follicular fluid placental growth factor is increased in polycystic ovarian syndrome: correlation with ovarian stimulation. Reprod Biol Endocrinol: RB&E. 2014;12:82. doi:10.​1186/​1477-7827-12-82.CrossRef
29.
Zurück zum Zitat Manau D, Balasch J, Jimenez W, Fabregues F, Civico S, Casamitjana R, et al. Follicular fluid concentrations of adrenomedullin, vascular endothelial growth factor and nitric oxide in IVF cycles: relationship to ovarian response. Hum Reprod (Oxford, England). 2000;15(6):1295–9.CrossRef Manau D, Balasch J, Jimenez W, Fabregues F, Civico S, Casamitjana R, et al. Follicular fluid concentrations of adrenomedullin, vascular endothelial growth factor and nitric oxide in IVF cycles: relationship to ovarian response. Hum Reprod (Oxford, England). 2000;15(6):1295–9.CrossRef
34.
Zurück zum Zitat Malickova K, Jarosova R, Rezabek K, Fait T, Masata J, Janatkova I, et al. Concentrations of sRAGE in serum and follicular fluid in assisted reproductive cycles—a preliminary study. Clin Lab. 2010;56(9–10):377–84.PubMed Malickova K, Jarosova R, Rezabek K, Fait T, Masata J, Janatkova I, et al. Concentrations of sRAGE in serum and follicular fluid in assisted reproductive cycles—a preliminary study. Clin Lab. 2010;56(9–10):377–84.PubMed
Metadaten
Titel
Follicular fluid soluble receptor for advanced glycation endproducts (sRAGE): a potential protective role in polycystic ovary syndrome
verfasst von
BiJun Wang
MengMeng Hao
QingLing Yang
Jing Li
YiHong Guo
Publikationsdatum
24.03.2016
Verlag
Springer US
Erschienen in
Journal of Assisted Reproduction and Genetics / Ausgabe 7/2016
Print ISSN: 1058-0468
Elektronische ISSN: 1573-7330
DOI
https://doi.org/10.1007/s10815-016-0704-6

Weitere Artikel der Ausgabe 7/2016

Journal of Assisted Reproduction and Genetics 7/2016 Zur Ausgabe

Hirsutismus bei PCOS: Laser- und Lichttherapien helfen

26.04.2024 Hirsutismus Nachrichten

Laser- und Lichtbehandlungen können bei Frauen mit polyzystischem Ovarialsyndrom (PCOS) den übermäßigen Haarwuchs verringern und das Wohlbefinden verbessern – bei alleiniger Anwendung oder in Kombination mit Medikamenten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Weniger postpartale Depressionen nach Esketamin-Einmalgabe

Bislang gibt es kein Medikament zur Prävention von Wochenbettdepressionen. Das Injektionsanästhetikum Esketamin könnte womöglich diese Lücke füllen.

Bei RSV-Impfung vor 60. Lebensjahr über Off-Label-Gebrauch aufklären!

22.04.2024 DGIM 2024 Kongressbericht

Durch die Häufung nach der COVID-19-Pandemie sind Infektionen mit dem Respiratorischen Synzytial-Virus (RSV) in den Fokus gerückt. Fachgesellschaften empfehlen eine Impfung inzwischen nicht nur für Säuglinge und Kleinkinder.

Update Gynäkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.